Companies Investors People

Drop to look up

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
For Startups
Alternatives

For iPhone and iPad

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Dealroom, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Terms of service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Longboard Pharmaceuticals/

Library

Longboard Pharmaceuticals

: 2020

Longboard Pharmaceuticals Website, Blog & Press Pages - aVenture Research

Library

longboardpharma.comCrawled Nov 11, 2026

Topics

Publication type

Search the library

Content origin

Row density

Product

2 pages

Expanded Access Policy/expanded-access-policy
Patients/patients
Longboard Pharmaceuticals collaborates globally with patients, families, advocates, and healthcare providers to address neurological conditions.

Press

6 pages

Longboard has been acquired by Lundbeck/longboard-has-been-acquired-by-lundbeck
On December 2, 2024, H. Lundbeck A/S announced the successful completion of the previously announced transaction to acquire all of the outstanding shares of Longboard Pharmaceuticals, Inc. With the completion of the acquisition, Longboard is now a
Longboard Pharmaceuticals Appoints Life Sciences Executive Dr. Jane Tiller to Board of Directors/longboard-pharmaceuticals-appoints-life-sciences-executive-dr-jane-tiller-to-board-of-directors
Nov 17, 2021 Download PDF Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Jane Tiller, MBChB, FRCPsych,
Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results/longboard-pharmaceuticals-provides-corporate-update-and-reports-full-year-2021-financial-results
The Phase 1b/2a PACIFIC Study evaluated LP352 in patients with developmental and epileptic encephalopathies, showing reduced epileptiform events in a Dravet syndrome model.
Longboard Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference/longboard-pharmaceuticals-to-present-at-the-h-c-wainwright-bioconnect-virtual-conference
Jan 5, 2022 Download PDF Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present at the H.C.

Careers & Hiring

1 page

Culture and Benefits/culture-and-benefits

About

2 pages

About/about
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, with an initial focus on rare diseases.
Our Approach/our-approach
Longboard Pharmaceuticals, originally formed by Arena Pharmaceuticals in January 2020, focuses on developing selective GPCR-targeted therapies.

Contact

1 page

Contact/contact
Reach out to discover more about Longboard Pharmaceuticals.

Homepage

1 page

Homepage/
Longboard Pharmaceuticals aims to develop treatments for neurological and rare diseases.

Privacy

1 page

Privacy Policy/privacy-policy
Longboard Pharmaceuticals’ Privacy Policy outlines how personal information may be collected from visitors to its corporate website.

Terms & Conditions

1 page

Terms of Use/terms-of-use